129 related articles for article (PubMed ID: 11999566)
1. CD52 expression in mantle cell lymphoma.
Bass AJ; Gong J; Nelson R; Rizzieri DA
Leuk Lymphoma; 2002 Feb; 43(2):339-42. PubMed ID: 11999566
[TBL] [Abstract][Full Text] [Related]
2. Different levels of CD52 antigen expression evaluated by quantitative fluorescence cytometry are detected on B-lymphocytes, CD 34+ cells and tumor cells of patients with chronic B-cell lymphoproliferative diseases.
Klabusay M; Sukova V; Coupek P; Brychtova Y; Mayer J
Cytometry B Clin Cytom; 2007 Sep; 72(5):363-70. PubMed ID: 17428002
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
Rodig SJ; Abramson JS; Pinkus GS; Treon SP; Dorfman DM; Dong HY; Shipp MA; Kutok JL
Clin Cancer Res; 2006 Dec; 12(23):7174-9. PubMed ID: 17145843
[TBL] [Abstract][Full Text] [Related]
4. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.
Zhang Z; Zhang M; Goldman CK; Ravetch JV; Waldmann TA
Cancer Res; 2003 Oct; 63(19):6453-7. PubMed ID: 14559836
[TBL] [Abstract][Full Text] [Related]
5. Emergence of CD52-, phosphatidylinositolglycan-anchor-deficient T lymphocytes after in vivo application of Campath-1H for refractory B-cell non-Hodgkin lymphoma.
Hertenstein B; Wagner B; Bunjes D; Duncker C; Raghavachar A; Arnold R; Heimpel H; Schrezenmeier H
Blood; 1995 Aug; 86(4):1487-92. PubMed ID: 7632956
[TBL] [Abstract][Full Text] [Related]
6. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells.
Rowan W; Tite J; Topley P; Brett SJ
Immunology; 1998 Nov; 95(3):427-36. PubMed ID: 9824507
[TBL] [Abstract][Full Text] [Related]
7. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.
Sánchez ML; Almeida J; Vidriales B; López-Berges MC; García-Marcos MA; Moro MJ; Corrales A; Calmuntia MJ; San Miguel JF; Orfao A
Leukemia; 2002 Aug; 16(8):1460-9. PubMed ID: 12145686
[TBL] [Abstract][Full Text] [Related]
8. CD52 expression in non-mycotic T- and NK/T-cell lymphomas.
Chang ST; Lu CL; Chuang SS
Leuk Lymphoma; 2007 Jan; 48(1):117-21. PubMed ID: 17325855
[TBL] [Abstract][Full Text] [Related]
9. A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma.
Khorana A; Bunn P; McLaughlin P; Vose J; Stewart C; Czuczman MS
Leuk Lymphoma; 2001 Mar; 41(1-2):77-87. PubMed ID: 11342359
[TBL] [Abstract][Full Text] [Related]
10. Phenotypic transformation of CD52(pos) to CD52(neg) leukemic T cells as a mechanism for resistance to CAMPATH-1H.
Birhiray RE; Shaw G; Guldan S; Rudolf D; Delmastro D; Santabarbara P; Brettman L
Leukemia; 2002 May; 16(5):861-4. PubMed ID: 11986948
[TBL] [Abstract][Full Text] [Related]
11. Quantitative evaluation of CD52 expression in B-cell chronic lymphocytic leukemia.
D'Arena G; Vigliotti ML; Matera R; Musto C; Iodice G; Tartarone A; Di Renzo N
Leuk Lymphoma; 2003 Jul; 44(7):1255-7. PubMed ID: 12916884
[No Abstract] [Full Text] [Related]
12. CD52 expression in hairy cell leukemia.
Quigley MM; Bethel KJ; Sharpe RW; Saven A
Am J Hematol; 2003 Dec; 74(4):227-30. PubMed ID: 14635201
[TBL] [Abstract][Full Text] [Related]
13. Immunophenotyping of leukemias using a cluster of differentiation antibody microarray.
Belov L; de la Vega O; dos Remedios CG; Mulligan SP; Christopherson RI
Cancer Res; 2001 Jun; 61(11):4483-9. PubMed ID: 11389079
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas.
Salisbury JR; Rapson NT; Codd JD; Rogers MV; Nethersell AB
J Clin Pathol; 1994 Apr; 47(4):313-7. PubMed ID: 8027367
[TBL] [Abstract][Full Text] [Related]
15. A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.
Lapalombella R; Zhao X; Triantafillou G; Yu B; Jin Y; Lozanski G; Cheney C; Heerema N; Jarjoura D; Lehman A; Lee LJ; Marcucci G; Lee RJ; Caligiuri MA; Muthusamy N; Byrd JC
Clin Cancer Res; 2008 Jan; 14(2):569-78. PubMed ID: 18223233
[TBL] [Abstract][Full Text] [Related]
16. Immunophenotype changes and loss of CD52 expression in two patients with relapsed T-cell prolymphocytic leukaemia.
Tuset E; Matutes E; Brito-Babapulle V; Morilla R; Catovsky D
Leuk Lymphoma; 2001; 42(6):1379-83. PubMed ID: 11911422
[TBL] [Abstract][Full Text] [Related]
17. CD52-Negative NK Cells Are Abundant in the Liver and Less Susceptible to Alemtuzumab Treatment.
Hotta R; Ohira M; Matsuura T; Muraoka I; Tryphonopoulos P; Fan J; Tekin A; Selvaggi G; Levi D; Ruiz P; Ricordi C; Vianna R; Ohdan H; Waldmann H; Tzakis AG; Nishida S
PLoS One; 2016; 11(8):e0161618. PubMed ID: 27560943
[TBL] [Abstract][Full Text] [Related]
18. Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia.
Piccaluga PP; Arpinati M; Candoni A; Laterza C; Paolini S; Gazzola A; Sabattini E; Visani G; Pileri SA
Leuk Lymphoma; 2011 Feb; 52(2):325-7. PubMed ID: 21077738
[No Abstract] [Full Text] [Related]
19. CD52 expression in T-cell large granular lymphocyte leukemia--implications for treatment with alemtuzumab.
Osuji N; Del Giudice I; Matutes E; Morilla A; Owusu-Ankomah K; Morilla R; Dunlop A; Catovksy D
Leuk Lymphoma; 2005 May; 46(5):723-7. PubMed ID: 16019510
[TBL] [Abstract][Full Text] [Related]
20. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia.
Osterborg A; Fassas AS; Anagnostopoulos A; Dyer MJ; Catovsky D; Mellstedt H
Br J Haematol; 1996 Apr; 93(1):151-3. PubMed ID: 8611450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
